Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9218739 | 0.87 | ALDH1A1 (0.59) | CYP2C9ALDH1A1HSD17B10TYRHIF1A | |
| SCHEMBL22593867 | 0.84 | ALDH1A1 (0.46) | CYP2C9ALDH1A1HSD17B10TYRHIF1A | |
| SCHEMBL12312062 | 0.80 | ADRB2 (0.50) | CYP2C9ALDH1A1HSD17B10HIF1ATSHR | |
| SCHEMBL14944003 | 0.80 | NOS3 (0.55) | CYP2C9ALDH1A1HSD17B10HIF1ATSHR | |
| SCHEMBL28851656 | 0.80 | ALDH1A1 (0.48) | CYP2C9ALDH1A1HSD17B10HIF1ATSHR | |
| SCHEMBL16906255 | 0.80 | ALDH1A1 (0.43) | CYP2C9ALDH1A1HSD17B10HIF1ATSHR | |
| SCHEMBL11060219 | 0.80 | ADRB2 (0.50) | CYP2C9ALDH1A1HSD17B10HIF1ATSHR | |
| SCHEMBL14175092 | 0.80 | ADRB2 (0.50) | CYP2C9ALDH1A1HSD17B10HIF1ATSHR | |
| SCHEMBL28196011 | 0.78 | ALDH1A1 (0.46) | CYP2C9ALDH1A1HSD17B10HIF1ATSHR | |
| SCHEMBL20251135 | 0.78 | RAB9A (0.50) | CYP2C9ALDH1A1TYRMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271243-A | Benzazepine compound and preparation method thereof | 浙大城市学院 | 2024-07-02 | — | — | CN | disclosed |
| US-11773052-B2 | Enamine compound and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-10-03 | — | — | US | disclosed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | disclosed |
| EP-3904424-A1 | POLY(ARYLENE ETHER KETONE) RESIN, PRODUCTION METHOD FOR SAME, AND MOLDED ARTICLE | DIC Corporation (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3353152-B1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2021-09-15 | — | — | EP | disclosed |
| EP-2094210-B2 | MEDICAL FABRIC | HARTMANN PAUL AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210252174-A1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2021-08-19 | — | — | US | disclosed |
| WO-2021074080-A1 | KIT COMPOSED OF A TWO-PART TISSUE ADHESIVE AND A TEMPORARY PROTECTIVE LINER THEREFOR, AND USE THEREOF | ADHESYS MEDICAL GMBH (DE) | 2021-04-22 | — | — | WO | disclosed |
| EP-3786207-A1 | ISOCYANATE FUNCTIONAL PRE-POLYMER FOR A BIODEGRADABLE TISSUE ADHESIVE | Adhesys Medical GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| EP-3385294-B1 | ISOCYANATE FUNCTIONAL PRE-POLYMER FOR A BIODEGRADABLE TISSUE ADHESIVE | ADHESYS MEDICAL GMBH (DE) | 2020-11-11 | — | — | EP | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| EP-2534187-A1 | ACTIVE SUBSTANCE-RELEASING WOUND DRESSING | Bayer Intellectual Property GmbH (DE) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098444-A1 | ACTIVE SUBSTANCE-RELEASING WOUND DRESSING | BAYER MATERIALSCIENCE AG (DE) | 2011-08-18 | — | — | WO | disclosed |
| EP-2094210-A2 | MEDICAL FABRIC | Paul Hartmann AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1962802-A1 | MEDICINAL COMPOSITION WITH ACTIVE INGREDIENTS AND WOUND CONTACT LAYER WITH A COMPOSITION | Paul Hartmann AG (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008080532-A2 | MEDICAL FABRIC | PAUL HARTMANN AG (DE) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161580-A1 | PROTECTED 3,5-DIHYDROXY-2,2-DIMETHYL-VALEROAMIDES FOR THE SYNTHESIS OF EPOTHILONES AND DERIVATIVES AND PROCESS FOR THE PRODUCTION AND THE USE | WESTERMANN JURGEN | 2008-07-03 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2007068492-A1 | MEDICINAL COMPOSITION WITH ACTIVE INGREDIENTS AND WOUND CONTACT LAYER WITH A COMPOSITION | PAUL HARTMANN AG (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773052-B2 | Enamine compound and use thereof | ENY2, AHR, PAH | CYP2C9 98/4885ALDH1A1 974/4885HSD17B10 348/4885 |
| US-20080161580-A1 | PROTECTED 3,5-DIHYDROXY-2,2-DIMETHYL-VALEROAMIDES FOR THE SYNTHESIS OF EPOTHILONES AND DERIVATIVES AND PROCESS FOR THE PRODUCTION AND THE USE | DHPS, VARS1, CYP51A1 | CYP2C9 673/4885ALDH1A1 1091/4885HSD17B10 20/4885 |
| US-20210252174-A1 | METHOD | MPI, DUT, NT5E | CYP2C9 2602/4885ALDH1A1 1340/4885HSD17B10 1738/4885 |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | CYP2C9 4824/4885ALDH1A1 4088/4885HSD17B10 2252/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | CYP2C9 841/4885ALDH1A1 852/4885HSD17B10 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.